阿帕替尼联合化疗对于晚期胃癌患者生存周期及血清sIL-2R、VEGF水平的影响

The effect of apatinib combined with chemotherapy on the survival cycle of patients with advanced gastric cancer and the serum levels of sIL-2R and VEGF

[目的]观察阿帕替尼联合化疗治疗晚期胃癌(GCA)患者临床疗效及对患者生存周期及血清白细胞介素-2受体(sIL-2R)、血管内皮生长因子(VEGF)水平的影响。[方法]选取我院2015年1月～2017年1月间收治的96例晚期GCA患者纳入本次研究,将入选患者随机分为对照组与观察组,对照组患者采取化学治疗(化疗),观察组在对照组的基础上联合阿帕替尼治疗,治疗6个化疗周期后评估2组临床疗效,观察治疗前后2组患者血清sIL-2R、VEGF水平的变化情况,统计2组患者不良反应发生情况;随访1年,统计对比2组患者无病进展生存时间(PFS)、总生存时间(OS)。[结果]观察组总缓解率(RR)52.08%、疾病控制率(DC)87.50%,对照组RR 27.08%、DC 50.00%,观察组临床疗效整体水平与RR、DC均优于对照组(P<0.05);治疗后,2组患者血清sIL-2R、VEGF表达水平均较本组治疗前明显改善,差异有统计学意义(P<0.05),观察组均低于对照组,差异有统计学意义(P<0.05);2组各项化疗不良反应发生率,差异无统计学意义;随访1年,观察组患者PFS、OS均长于对于对照组(P<0.05)。[结论]阿帕替尼联合化疗能够提高晚期GCA患者的临床疗效,降低血清sIL-2R、VEGF表达水平,延缓患者病情进展、延长患者总生存时间。

[Objective]To observe the clinical efficacy of apatinib combined with chemotherapy in the treatment of advanced gastric cancer and its effects on the survival cycle,serum interleukin-2receptor(sIL-2R)and vascular endothelial growth factor(VEGF)levels.[Methods]96patients with advanced gastric cancer admitted to our hospital between January 2015 and January 2017 were included in this study,all the patients were divided into the control group and the observation group random.The control group was treated with chemotherapy,and the observation group was combined with apatinib on the basis of the control group,the clinical efficacy of the two groups was evaluated after 6chemotherapy cycles,and the changes in serum sIL-2Rand VEGF levels of the two groups before and after treatment were observed,and the adverse reactions of the two groups were statistically analyzed;the patients were followed up for one year,and the PFS and OS were statistically compared between the two groups.[Results]The RR rate of the observation group was 52.08%,the DC rate was 87.50%,the RR rate of the control group was 27.08%,and the DC rate was 50.00%,the overall level of clinical efficacy,RR and DC of the observation group were better than those of the control group,P<0.05;after treatment,the expression levels of serum sIL-2R and VEGF in both groups were improved compared with those before treatment(P<0.05intra-group),while those in the observation group were lower than those in the control group(P<0.05intra-group);there was no statistical difference in the incidence of various adverse reactions of chemotherapy between the two groups,P>0.05;after one year of follow-up,PFS and OS in the observation group were longer than those in the control group,P<0.05.[Conclusion]Apatinib combined with chemotherapy can improve the clinical efficacy of patients with advanced gastric cancer,reduce the expression levels of serum sIL-2Rand VEGF,delay the progression of the disease and extend the total survival time of the patients.